BioLineRx (BLRX) Total Current Liabilities (2021 - 2025)

BioLineRx has reported Total Current Liabilities over the past 5 years, most recently at $12.1 million for Q4 2025.

  • Quarterly results put Total Current Liabilities at $12.1 million for Q4 2025, down 21.31% from a year ago — trailing twelve months through Dec 2025 was $12.1 million (down 21.31% YoY), and the annual figure for FY2025 was $12.1 million, down 21.31%.
  • Total Current Liabilities for Q4 2025 was $12.1 million at BioLineRx, down from $15.4 million in the prior quarter.
  • Over the last five years, Total Current Liabilities for BLRX hit a ceiling of $42.8 million in Q4 2023 and a floor of $9.7 million in Q4 2021.
  • Median Total Current Liabilities over the past 5 years was $12.1 million (2025), compared with a mean of $18.1 million.
  • Biggest five-year swings in Total Current Liabilities: soared 300.64% in 2023 and later plummeted 63.99% in 2024.
  • BioLineRx's Total Current Liabilities stood at $9.7 million in 2021, then increased by 9.88% to $10.7 million in 2022, then soared by 300.64% to $42.8 million in 2023, then plummeted by 63.99% to $15.4 million in 2024, then fell by 21.31% to $12.1 million in 2025.
  • The last three reported values for Total Current Liabilities were $12.1 million (Q4 2025), $15.4 million (Q4 2024), and $42.8 million (Q4 2023) per Business Quant data.